Literature DB >> 10571250

Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1).

C Bruhn1, J Brockmöller, I Cascorbi, I Roots, H H Borchert.   

Abstract

Arylamine N-acetyltransferase 1 (NAT1) conjugates several aromatic amines and their N-hydroxylated metabolites by N- or O-acetylation. NAT1 genotype and phenotype is known to be variable in human populations. In this study, we set out to measure the functional relevance of the frequent NAT1 gene variants for the activity in human red blood cells. Healthy German volunteers (N = 314) were genotyped for NAT1 alleles *3, *4, *10, *11, *14, and *15 using polymerase chain reactions and restriction fragment length pattern analysis, and NAT1 enzyme kinetic parameters were measured in a subset of 105 individuals using p-aminobenzoic acid as specific substrate. There was no functional difference between NAT1 alleles *4 and *10. In particular, there was no trend of increasing activity from NAT1*4/*4 to *4/*10 and *10/*10. Carriers of the NAT1 *11 and *14 alleles had a statistically significant lower enzyme activity compared with carriers of the *3, *4, or *10 alleles. Compared with the wild-type genotype NAT1*4/*4, activity of the NAT1*11/*11, NAT1*11/*10, and NAT1*11/*4 genotypes was reduced by 20.7%, 35.7%, and 31.5%, respectively. Activity of the NAT1*10/*14 and NAT1*4/*14 genotypes was reduced by 49.8% and 55.6%, respectively. The difference in NAT1 activity between the *4/*11 and *4/*14 genotypes was also significant (P < 0.01). The carrier of the NAT1*15/*15 genotype had no detectable enzyme activity. In conclusion, functional consequences of NAT1 mutations were tested in a large population. Activity in carriers of NAT1 alleles *3, *4, and *10 did not differ, alleles NAT1*11 and *14 appeared to be low activity alleles, and allele NAT1*15 had no activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571250     DOI: 10.1016/s0006-2952(99)00269-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  23 in total

Review 1.  A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review.

Authors:  Chunming Gong; Xueying Hu; Yong Gao; Yunfei Cao; Feng Gao; Zengnan Mo
Journal:  Med Oncol       Date:  2010-01-23       Impact factor: 3.064

Review 2.  Pharmacogenetics in inflammatory bowel disease.

Authors:  Marie Pierik; Paul Rutgeerts; Robert Vlietinck; Severine Vermeire
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

3.  Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1.

Authors:  David F Barker; Anwar Husain; Jason R Neale; Benjamin D Martini; Xiaoyan Zhang; Mark A Doll; J Christopher States; David W Hein
Journal:  Pharmacogenet Genomics       Date:  2006-07       Impact factor: 2.089

4.  Carcinogen metabolism, cigarette smoking, and breast cancer risk: a Bayes model averaging approach.

Authors:  Nadine Stephenson; Lars Beckmann; Jenny Chang-Claude
Journal:  Epidemiol Perspect Innov       Date:  2010-11-16

5.  Mesalazine pharmacokinetics and NAT2 phenotype.

Authors:  Hendrik Lück; Martina Kinzig; Alexander Jetter; Uwe Fuhr; Fritz Sörgel
Journal:  Eur J Clin Pharmacol       Date:  2008-08-14       Impact factor: 2.953

6.  Modification by N-acetyltransferase 1 genotype on the association between dietary heterocyclic amines and colon cancer in a multiethnic study.

Authors:  Lesley M Butler; Robert C Millikan; Rashmi Sinha; Temitope O Keku; Scott Winkel; Brent Harlan; Allison Eaton; Marilie D Gammon; Robert S Sandler
Journal:  Mutat Res       Date:  2007-10-13       Impact factor: 2.433

7.  Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer.

Authors:  Li Jiao; Mark A Doll; David W Hein; Melissa L Bondy; Manal M Hassan; James E Hixson; James L Abbruzzese; Donghui Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-11       Impact factor: 4.254

8.  Polymorphism of N-acetyltransferase 1 and correlation between genotype and phenotype in a Thai population.

Authors:  Veerapol Kukongviriyapan; Auemduan Prawan; Benjamart Warasiha; Wichittra Tassaneyakul; Jareerat Aiemsa-ard
Journal:  Eur J Clin Pharmacol       Date:  2003-07-19       Impact factor: 2.953

9.  Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements.

Authors:  Anwar Husain; Xiaoyan Zhang; Mark A Doll; J Christopher States; David F Barker; David W Hein
Journal:  Drug Metab Dispos       Date:  2007-06-25       Impact factor: 3.922

Review 10.  N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine.

Authors:  David W Hein
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-04       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.